Skip to main content

BIOLIFE SOLUTIONS INC

corporate_fare Company Profile

BIOLIFE SOLUTIONS INC

BLFS·NASDAQ·Industrial Applications And Services·CIK 0000834365

We are a life sciences company that develops, manufactures, and markets bioproduction products and services. These offerings are designed to improve quality and reduce risks in biologic manufacturing, distribution, and transportation within the cell and gene therapy (CGT) industry. Our products are utilized in basic and applied research, as well as in the commercial manufacturing of biologic-based therapies. Customers use our products to maintain the health and function of biologic material during sourcing, manufacturing, and distribution. We currently operate as a single bioproduction products and services business, supporting various steps in the biologic material manufacturing and delivery process. Our portfolio includes biopreservation media and cell processing products. We possess in-house expertise in cryobiology and the broader CGT workflow. On October 6, 2025, the Company entered into a Limited Liability Company Membership Interest Purchase Agreement with Peli BioThermal LLC for the sale of all issued and outstanding limited liability company membership interests of SAVSU Cleo Technologies, LLC. This divestiture included our evo cloud-connected "smart" shipping container products, which provided passive storage and transport for temperature-sensitive biologics and pharmaceuticals. The SAVSU business is presented as a discontinued operation for all periods presented in the accompanying Consolidated Financial Statements. On April 4, 2025, pursuant to a Stock Purchase Agreement, the Company's wholly owned subsidiary, 2699979 Alberta LTD., acquired PanTHERA CryoSolutions Inc.

BIOLIFE SOLUTIONS INC (NASDAQ:BLFS) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 23 items for BLFS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • BioLife Solutions Reports Full Year 2025 Results, Details Strategic Portfolio Shifts and Internal Control Remediation
  • BioLife Solutions Reports Strong Q4 & FY25 Results, Guides for 2026 GAAP Profitability
  • BioLife Solutions Exceeds Full Year 2025 Revenue Guidance with Strong Q4 Growth

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$96.21M
Net Income
-$4.59M
Diluted EPS
-$0.10
Op. Cash Flow
$20.11M
Free Cash Flow
$10.64M
Gross Profit
$62.12M
Operating Income
-$16.6M
Cash & Equivalents
$33.04M
Total Debt
$5M
Debt / Equity
0.01×
Net Margin
-4.8%
Shares Outstanding
48.2M sh
Source: 10-K · filed 2026-04-28 · accession 0001628280-26-028012
$34.95
52-week range · as of 2026-09-09 $17.86 – $38.1
Market cap
$1.71B
Volume
968K (1.3× avg)
3-mo avg 749K
Live data · 2026-09-14 00:04 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BLFS - Filings & News (Page 2)

BLFS
Feb 26, 2026, 4:15 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $23.50
Real-time Price: $34.95 info
Change: +$11.45 (+49%) info
Market Cap: $1.71B info
BLFS
Feb 26, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $23.08
Real-time Price: $34.95 info
Change: +$11.87 (+51%) info
Market Cap: $1.71B info
BLFS
Jan 12, 2026, 8:04 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.65
Real-time Price: $34.95 info
Change: +$9.30 (+36%) info
Market Cap: $1.71B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets